- Must have BMI of 40 or less
- Must have a history of Irritable Bowel Syndrome
- Cannot have Type I or II Diabetes or thyroid disorder
The purpose of this study is to assess an investigational medication called olorinab in the treatment of abdominal pain in individuals with irritable bowel syndrome (IBS). IBS is an intestinal (gut) disorder associated with pain in the belly, gas, and diarrhea and/or constipation. There is no cure for IBS. Many patients with IBS report abdominal pain as their most severe IBS symptom. There have been attempts to treat IBS related pain with certain pain medications such as opioids, gabapentin, and tricyclic antidepressants (TCAs) but these treatment options have resulted in limited success, primarily due to side effects of these medications. These types of treatment may help improve IBS-related pain for some patients, but for others, they may not. For some patients, existing treatments may help to initially improve pain symptoms, but symptoms may reappear over time. Therefore, there is a need for new treatment options for patients with IBS-related pain.
Olorinab has been previously tested in healthy individuals and in patients with Crohn’s disease (a different bowel disease that is associated with abdominal pain). It is now being tested in patients with IBS.